Thyrotoxicosis generally presents with classic signs and symptoms in younger people. Among the elderly population atypical presentation is recognized, although this has not been well quantified or characterized. To avoid misdiagnosis or delay in diagnosis, clinical suspicion needs to remain high.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12968/hosp.1999.60.2.1808 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pediatric Graves' disease in Argentina: analyzing treatment strategies and outcomes.
J Pediatr Endocrinol Metab
December 2024
CONICET-FEI-División de Endocrinología, Centro de Investigaciones Endocrinológicas"Dr. César Bergadá" (CEDIE), Hospital de Niños Ricardo Gutiérrez, BuenosAires, Argentina.
Objectives: Graves' disease is the leading cause of hyperthyroidism in children. Only a small percentage of pediatric patients achieve remission with anti-thyroid drug treatment (ATD), and both definitive therapies (thyroidectomy, or radioiodine thyroid ablation) cause lifelong hypothyroidism. Our objective was to evaluate the outcome of patients with pediatric Graves' disease (PGD), treated at a single tertiary center, focusing on response to medical treatment, remission rate, adverse reactions (AR), definitive treatment (DT), and potential predictive factors for remission.
View Article and Find Full Text PDFSignificance of Thyroid Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves' Disease.
J Clin Endocrinol Metab
December 2024
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- TSI and TRAb are important biomarkers for diagnosing Graves' disease (GD), but their clinical impact needs further exploration.
- A study analyzed medical records to understand the relationship between these antibodies, thyroid function, and relapse rates in GD patients.
- Results showed a strong correlation between TSI and TRAb, and patients with positive TSI levels had a higher risk of relapse after stopping antithyroid drugs, suggesting that negative levels of both antibodies indicate better outcomes.
Clinical and genetic characteristics of patients with monocarboxylate transporter-8 deficiency: a multicentre retrospective study.
Eur J Pediatr
December 2024
Department of Pediatric Endocrinology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Unlabelled: Allan-Herndon-Dudley syndrome is a neurodevelopmental disorder characterized by motor and intellectual disabilities. Despite its rarity, there has been a rise in interest due to ongoing research and emerging therapy suggestions. In this multicenter, retrospective, cross-sectional study, the genetic characteristics and clinical data of twenty-one cases of genetically confirmed MCT8 deficiency were evaluated.
View Article and Find Full Text PDFSwallowing Assessment in a Pediatric Case of Allan-Herndon-Dudley Syndrome (MCT8 Deficiency): Advanced Insights into Dysphagia via Flexible Endoscopic Evaluation of Swallowing.
Neuropediatrics
January 2025
Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics and Adolescent Medicine, KJF Klinikum Josefinum, Augsburg, Germany.
Patients with MCT8 deficiency often present with underweight and are prone to frequent pulmonary infections, including aspiration pneumonia. Despite commonly reported swallowing difficulties in this population, specific dysphagia symptoms have not been well-documented. We conducted a flexible endoscopic evaluation of swallowing (FEES) on a young boy diagnosed with MCT8 deficiency, who exhibited recurrent pulmonary infections and failed to achieve substantial weight gain despite an oral energy intake appropriate for his age and height.
View Article and Find Full Text PDFEfficacy of a fixed low dose of radioactive iodine in the treatment of Graves' disease in Sub-Saharan Africa.
Hell J Nucl Med
December 2024
Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Objective: Graves' disease represents 60%-90% of all causes of thyrotoxicosis in different regions of the world. Thyrotoxicosis contributes approximately 66% to thyroid disorders in South Africa and of those Graves' disease contributes about 34%. In most Sub-Saharan African countries, Graves' disease is managed mainly with medical treatment, due to a lack of or poor access to other means of treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!